Form 4: Arbutus Biopharma CEO Granted Significant Equity Awards

Arbutus Biopharma's President and CEO, Lindsay Androski, received significant equity awards including restricted stock units and stock options.

Summary

• Lindsay Androski, President and CEO of Arbutus Biopharma Corp (ABUS), was granted 28,000 common shares in the form of Restricted Stock Units (RSUs) on February 2, 2026.
• These RSUs represent a contingent right to receive one common share for each unit and vest in three equal annual installments, beginning one year from the grant date, subject to continuous service.
• Androski was also granted stock options to purchase 71,700 common shares with an exercise price of $4.39 per share, reflecting the closing price on the Nasdaq Stock Market on the grant date.
• The stock options vest over a four-year period, with 1/48th of the shares vesting in substantially equal monthly installments commencing one month after the grant date, subject to continuous service.
• The stock options have an expiration date of February 2, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for corporate governance and management alignment, as significant equity awards incentivize the CEO to drive long-term shareholder value.

Positives

• The grant of restricted stock units and stock options aligns the CEO's long-term interests with those of shareholders, incentivizing performance.
• Equity compensation is a standard practice for attracting and retaining top executive talent in the biotechnology industry.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on executive compensation.

Industry Context

StockSavvy.ai notes that the granting of equity awards, such as RSUs and stock options, is a common and widely accepted practice within the biotechnology and pharmaceutical industries. This compensation structure is designed to align executive incentives with long-term shareholder value creation, particularly in sectors with long development cycles and high R&D costs.

Comparison to Industry Standards

• The structure of these equity grants, including multi-year vesting schedules for both RSUs and stock options, is consistent with typical executive compensation packages observed across the biotechnology sector, such as those at comparable companies like Alnylam Pharmaceuticals or Moderna, which frequently use similar long-term incentive plans to retain and motivate key personnel.

Stakeholder Impact

• Shareholders: The equity grants are intended to align the CEO's interests with shareholders, potentially leading to improved long-term performance and value creation.
• Employees: While not directly impacting all employees, executive compensation practices can influence overall company morale and compensation strategies.

Next Steps

• The granted Restricted Stock Units will vest in three equal annual installments, beginning one year from the grant date.
• The granted stock options will vest over a four-year period, with monthly installments commencing one month after the grant date.

Key Dates

Keywords

Arbutus Biopharma, ABUS, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Executive Compensation, Biopharma